EKF Diagnostics - Interim results

Tuesday, Oct 04 2011 by

EKF Diagnostics, the point of care diagnostics company, announced that Interim results to June 2011 (with pro-forma comparative results) showed sales of £7.4 million (2010: £6.0 million) and adjusted EBITDA of £210,000 (2010: £(51,000)). The pre-tax loss was £1.55 million (2010: £(302,000)), actual not pro-forma.

The company reported that the period was impacted by the costs involved in moving from an essentially owner-managed structure and culture to one that is more reflective of the demands of a higher-growth/higher governance led environment. Gross margin was 64% (2010: 58%). Period end net cash was £2.8 million.

The EKF share price has increased by 3% over the past year.

EKF Diagnostic Holdings Plc is currently graded C by LCF Research. To learn more, follow the link.


Disclaimer:  

This note was prepared by LCF Research Limited using information provided by the subject company’s management or publically available news sources. No representations are made nor warranties given (express or implied) in relation to accuracy and completeness. This document is not an invitation to invest in the subject company and does not purport to contain all the necessary information that a prospective investor might require. LCF Research Limited recommends prospective investors to conduct their own thorough independent analysis of the subject company and the information contained in this note or referred to above.


Do you like this Post?
Yes
No
0 thumbs up
0 thumbs down
Share this post with friends



EKF Diagnostics Holdings plc is engaged in developing, manufacturing and supplying of products and services into the in-vitro diagnostic (IVD) market place. The Company manufactures and sells diagnostic instruments, reagents and certain ancillary products. The Company's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. The Company's Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen C-Line and Biosen S-Line, STAT-Site M B-HB analyzer, sTNFR1 biomarker test kits and Altair 240. more »

LSE Price
17.25p
Change
-0.7%
Mkt Cap (£m)
72.8
P/E (fwd)
25.2
Yield (fwd)
n/a



  Is EKF Diagnostics Holdings fundamentally strong or weak? Find out More »


What's your view on this thread? Log In to Comment Now

You can track all @StockoChat comments via Twitter




Stock Picking Tutorial Centre



Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis
Foliobuilder